Pharmaceuticals

Legal update – UK IPO COVID-19 response

Legal update – UK IPO coronavirus response In recognition of the challenges individuals and businesses are facing amidst the coronavirus outbreak, the UK Intellectual Property Office (UK IPO) has made certain temporary adjustments to its practices, to ensure that parties are not adversely affected in their dealings with the Office. It has also had to… Read more »

Artificial Intelligence – Our March 2020 report

Artificial Intelligence – Our March 2020 report According to the European Patent Office, for the first time in more than a decade, digital technologies have taken the lead in patent applications filed. Among the top technical fields digital communication (+19.6%) and computer technology (+10.2%) saw the steepest growth. The report, published on the 12th March… Read more »

BioScience Today article: Shanks v Unilever – An opening of the claim floodgates?

Solicitor Varuni Paranavitane writes for BioScience Today on the subject of Shanks v Unilever – An opening of the claim floodgates? This article was originally written for BioScience today, you can find Varuni’s article below, or read the full magazine here.   BACKGROUND In 2006 Professor Shanks claimed compensation under s40 of the Patents Act on… Read more »

News in brief from the pharma and medical devices sectors – Summer 2019 trade mark decisions from the UK and EU

Senior Associate Suzanne Power reports on the Summer 2019 trade mark decisions from the UK and EU in the Pharma and Med Dev sectors. 1. Slogans remain difficult to register as EU trade marks – Case T-555/18 of 3 April 2019, Medrobotics Corp. v EUIPO This decision from the EU’s General Court (“GC”) highlights the… Read more »

AA Thornton are ranked in the Legal 500 2020

AA Thornton is ranked as a top tier firm The Legal 500 2020 edition has now been published and we are absolutely delighted to be recommended as a top-tier firm for our trade marks practice, which was described as “strong”, “dedicated” and an “excellent team of knowledgeable and genuinely good people”. We also remain highly recommended for our patents… Read more »

Biosimilars and patents

The majority of the world’s biggest selling medicines can be classified as “biologics” or “biopharmaceuticals”. Such medicines contain one or more biologically active product produced from (or containing components of) living organisms as the active ingredients.   Biosimilars are biological products which are highly similar in structure, biological activity, efficacy, safety and immunogenicity profile to… Read more »

Patent protection of medical devices

Patent protection of medical devices – time for a rethink? This article was first published by Bio Science Today in March 2019 Introduction The duration of patent protection for medical devices is up to twenty years, as for any other type of device. Pharmaceuticals, on the other hand, may be entitled to an extended duration… Read more »

Legal update: Eli Lilly v Genentech – Warner-Lambert

Eli Lilly v Genentech – Warner-Lambert Supreme Court Plausibility Test Applied Following the highly anticipated Supreme Court decision in Warner-Lambert v Generics in relation to plausibility at the end of last year, the UK High Court has recently applied the new plausibility test for the first time in Eli Lilly v Genentech Inc.1 Eli Lilly… Read more »

Julie Barrett-Major speaks at Queen Mary University

Reporting on the Queen Mary University’s Life Sciences, Cosmetics and Intellectual Property seminars for CNIPA Consulting Patent Attorney Julie Barrett-Major recently gave two 3-hour seminars at the Queen Mary University of London (QMUL) earlier this month on Life Sciences, Cosmetics and Intellectual Property. The two seminars formed part of the QMUL’s programme of education and training… Read more »

Categories

Archives